February 24, 2024

USPTO Issues Notice of Allowance to Enveric Biosciences for C4-Carboxylic Acid-Substituted Tryptamine Derivatives

Editor’s note- Server issues delayed the posting of this news alert

(24/7 MARKET NEWS) – Enveric Biosciences, Inc. (NASDAQ:ENVB) stated, this morning, that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series, the second Notice of Allowance from the USPTO for intellectual property governing the EVM201 Series.

Enveric Biosciences is trading at $3.62, up $0.47 (+14.92%), on 18.7K premarket shares traded.

Its 52-week range is $1.30 to $18.50. It traded over 100 million shares on the 18th, so there should be a lot of resistance pockets between here and $4.50, but if it can break through the $4.50 highs from the 18th and 19th, on stronger volume, this could try to make a run to the $6+ level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.